Investor Shay Capital LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Shay Capital LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-08-14 13G/A TLYS / Tilly's, Inc. 2,726,744 3,390,000
2025-05-29 13G OKUR / OnKure Therapeutics, Inc. 810,214
2025-05-27 13G/A TLYS / Tilly's, Inc. 2,279,000 2,726,744
2025-04-17 13G CTRN / Citi Trends, Inc. 441,970
2025-02-14 13G/A TLYS / Tilly's, Inc. 1,926,785 2,279,000
2025-02-14 13G/A XELA / Exela Technologies, Inc. 523,801 175,600
2025-02-14 13G/A NVRO / Nevro Corp. 1,969,797 1,571,762
2024-12-04 13G NVRO / Nevro Corp. 1,969,797
2024-02-14 13G/A TLYS / Tilly's, Inc. 1,129,862 1,926,785
2024-02-14 13G/A TBCH / Turtle Beach Corporation 1,220,000 863,628
2024-02-14 13G/A GRPN / Groupon, Inc. 1,892,100 478,602
2024-02-14 13G/A XELA / Exela Technologies, Inc. 523,801
2023-09-29 13G TBCH / Turtle Beach Corporation 614,784 1,220,000
2023-08-03 13G GRPN / Groupon, Inc. 1,892,100
2023-02-14 13G/A TBCH / Turtle Beach Corporation 864,998 614,784
2023-02-14 13G/A PMCB / PharmaCyte Biotech, Inc. 1,037,882 0
2023-02-13 13G XELA / Exela Technologies, Inc. 8,250,000
2023-02-13 13G TLYS / Tilly's, Inc. 1,129,862
2022-10-20 13G PMCB / PharmaCyte Biotech, Inc. 1,037,882
2022-07-05 13G HEAR / Turtle Beach Corporation 864,998
2022-02-10 13G/A HYRE / HyreCar Inc 1,267,445 957,546
2021-04-21 13G HYRE / HyreCar Inc 1,267,445